Member Companies2018-08-13T18:10:31+00:00

Member Companies

Rebiotix Inc.

About Rebiotix

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized non-frozen, oral capsule formulation, which is currently moving into a Phase 2 IND trial for the prevention of recurrent C. diff infection having completed an investigator sponsored Phase 1 study. In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ platform. The MRT™ platform is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format.

Target Indications
Recurrent C. Diff prevention
VRE Elimination
Pediatric Ulcerative Colitis
Multi-drug Resistant UTI
Hepatic Encephalopathy
Recurrent C. Diff Prevention

Leadership
Lee Jones – Founder, President, and Chief Executive Officer
Dale N. Gerding, M.D., MACP, FIDSA, FSHEA – Chief Medical Officer
Ken F. Blount, Ph.D. – Chief Scientific Officer
Edward S. Burd, Ph.D. – Head of Regulatory Affairs
Nancy Timm, VP of Finance and Operations

Contact
http://www.rebiotix.com/
info@rebiotix.com
Twitter: @Rebiotix

Seres Therapeutics

About Seres

Seres Therapeutics, Inc. (NASDAQ:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection.  Seres is also developing SER-401 to augment the efficacy of immuno-oncology treatment.

 

Target Indications
C. difficile
Ulcerative Colitis
Inflammatory bowel disease
Cancer

Leadership
Roger Pomerantz, M.D. – President, Chief Executive Officer and Chairman of the Board of Directors
Eric Shaff – Executive Vice President, Chief Operating and Financial Officer
John Aunins, Ph.D. – Executive Vice President, Bioprocess & Manufacturing and Chief Technology Officer
David Cook, Ph.D. – Executive Vice President, Chief Scientific Officer
Thomas J. DesRosier, Esq. – Executive Vice President, Chief Legal Officer and Secretary
Matthew Henn, Ph.D. – Executive Vice President, Microbiome Research and Development
Henry Rath – Senior Vice President, Head of Corporate Development

Contact
http://www.serestherapeutics.com/
info@serestherapeutics.com
Twitter: @SeresTX

Vedanta Biosciences

About Vedanta

Vedanta Biosciences is developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortia of human microbiome-derived bacteria. Vedanta Biosciences is a leader in the microbiome field with capabilities and deep expertise to discover, develop, and manufacture live bacteria drugs. These include what is believed to be the largest collection of human microbiome-associated bacterial strains, a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form.

Vedanta Biosciences’ pioneering work, in collaboration with its scientific co-founders, has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells, CD8+ T cells, and Th17 cells, among others. These advances have been published in leading peer-reviewed journals including Science (multiple), Nature (multiple), Cell and Nature ImmunologyVedanta Biosciences has harnessed these biological insights and its capabilities to generate a pipeline of programs in infectious disease, autoimmune disease, allergy, and immune-oncology.

Target Indications
C. Difficile
Inflammatory Bowel Disease
Food Allergy
Multi-drug Resistant Organisms and Graft-vs-Host Disease
Cancer Immunotherapy
Non-alcoholic fatty liver disease and steatohepatitis

Leadership
Bernat Olle, Ph.D. – Chief Executive Officer
Bruce Roberts, Ph.D. – Chief Scientific Officer
Dan Couto – Chief Technical Officer
Erik Spek, Ph.D., J.D. – VP, Head of Intellectual Property
Dmitri Bobilev, M.D. – VP, Clinical Development